(Q43235034)

16 November 2017

title

Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study (English)

1 reference

16 November 2017

1 reference

1 reference

4

1 reference

16 November 2017

Grigori Joffe

7

0 references

author name string

Jan-Henry Stenberg

1

1 reference

16 November 2017

Viatcheslav Terevnikov

2

1 reference

16 November 2017

Marina Joffe

3

1 reference

16 November 2017

Evgueni Tchoukhine

5

1 reference

16 November 2017

Mark Burkin

6

1 reference

16 November 2017

publication date

27 November 2009

1 reference

The International Journal of Neuropsychopharmacology

16 November 2017

published in

1 reference

16 November 2017

volume

13

1 reference

16 November 2017

issue

4

1 reference

16 November 2017

page(s)

433-441

1 reference

Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Recent advances in treating cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

A deficit profile of executive, memory, and motor functions in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

A direct approach to false discovery rates

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

The neuropsychological signature of schizophrenia: generalized or differential deficit?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Investigation of serum BDNF levels in drug-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

A Review of the Pharmacological and Clinical Profile of Mirtazapine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Neurocognitive functioning in patients with first-episode schizophrenia : results of a prospective 5-year follow-up study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Stability of cognitive functioning early in the course of schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: short- and long-term memory.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

How should DSM-V criteria for schizophrenia include cognitive impairment?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

The Stroop color-word test: a review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Medicine. What are the right targets for psychopharmacology?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Correlates of cognitive deficits in first episode schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

A Standardized Memory Scale for Clinical Use

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Pharmacological treatment of cognition in schizophrenia: an idea whose method has come

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Longitudinal studies of cognition in schizophrenia: meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990897

7 January 2021

10.1017/S1461145709990897

Identifiers

DOI

1 reference

16 November 2017

1 reference